Prognostic efficacy of lymph node parameters in resected ampullary adenocarcinoma based on long-term follow-up data after adjuvant treatment

Table 1 Clinicopathologic characteristics of patients who underwent curative resection for ampullary adenocarcinoma

Characteristics	N = 86
Age	59.0 (55.0–64.0)
≥ 60	39 (45.3%)
< 60	47 (54.7%)
Gender
Male	46 (53.5%)
Female	40 (46.5%)
Performance status (ECOG)
0–1	83 (96.5%)
2	3 (3.5%)
Type of surgery
PPPD	76 (88.4%)
Whipple	10 (11.6%)
Tumor differentiation
Well differentiated	9 (10.5%)
Moderately differentiated	65 (75.6%)
Poorly differentiated	12 (13.9%)
Tumor size (cm)	2.1 (1.6–2.8)
Number of dissected LNs	15 (8–25)
pT stage
1–2	35 (40.7%)
3–4	51 (59.3%)
pN stage
0	44 (51.2%)
1	33 (38.4%)
2	9 (10.5%)
Microscopic lymphatic invasion
Present	47 (54.7%)
Venous invasion
Present	7 (8.1%)
Perineural invasion
Present	24 (27.9%)
Preoperative CA 19-9^a
≤ 37	53 (61.6%)
> 37	33 (38.4%)
Postoperative CA 19-9^b
≤ 37	79 (91.9%)
> 37	7 (8.1%)
Adjuvant CCRT	75 (87.2%)
Additional chemotherapy after CCRT
FL	1 (1.2%)
XP	1 (1.2%)

ECOG Eastern Cooperative Oncology Group, LN lymph node, CA 19–9 carbohydrate antigen 19–9, CCRT concurrent chemoradiation therapy, PPPD pylorus preserving pancreaticoduodenectomy, FL fluorouracil and folinic acid, XP capecitabine and cisplatin
^aPreoperative CA 19–9 refers to the value measured within one month before surgery, with the closest value to the surgery date
^bPostoperative CA 19–9 refers to the CA 19–9 value measured at the first outpatient follow-up visit after recovery from surgery

ISSN: 1477-7819